Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY232 in relapsed/refractory multiple myeloma
NCT07336823Phase 1Recruiting
- Sponsor
- Genocury Biotech
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of JY232 in multiple myeloma (MM), sponsored by Genocury Biotech. Primary endpoints: Incidence of Treatment Related adverse events at 2 years and Maximum Tolerated Dose at 28 days. Started Jan 2026; status: recruiting.
02
Drugs
JY232
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07336823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336823.